Valuation
- Market cap
- 1,242,087,000
- Revenue TTM
- $30,409,000
- Net income TTM
- $840,000
- P/E (trailing)
- 10.46
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 615,402
- Avg volume
- 829,846
- Day's range
- $9.94 – $10.70
- Shares out
- 107,447,000
- Stochastic %K
- 30%
- Beta
- 0.60
- Analysts
- Strong Buy
- Price target
- $18.00
Company profile
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as t...
Show more
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 650 446 6630
- Website
- https://www.freenome.com
- Address
- 3300 Marina Boulevard, Brisbane, United States
Latest news
No headlines yet.
